Neurocrine Biosciences Inc. has described new vesicular monoamine transporter 2 (VMAT2) inhibitors reported to be useful for the treatment of neurological and psychiatric disorders, among others.
University of Calgary scientists described their work on a small peptide aptamer 8 to bind cellular prion protein and prevent its binding with β-amyloid oligomers, an interaction that activates tyrosine-protein kinase Fyn and neuroinflammation.
Recent studies have pointed to the role of GPR39 expression in antidepressant treatment, but little is known about the interactions between specific receptors.
mPGES-1 is overexpressed in the dopaminergic neurons of the substantia nigra pars compacta of post-mortem brain tissue from patients with Parkinson’s disease (PD) as well as in 6-hydroxydopamine (6-OHDA)-injected PD mice.
Columbia University has presented non-hallucinogenic ariadne analogues acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, among other disorders.
C2orf82, also known as small novel rich in cartilage (SNORC), is a gene located on chromosome 2 that is known to play a role in chondrocyte maturation.
At first blush, to say that depression occurs with other diseases may seem like belaboring the obvious. After all, to put it in the bluntest possible terms, it’s sad to be sick. But by looking more closely, it soon becomes clear that the association is stronger than that. The strongest association between depression and other diseases, Stefan Gold told the audience at the European College of Neuropsychopharmacology (ECNP) annual conference in Vienna this week, is “not necessarily the most severe or most immediately life-threatening disorders… [it’s] across the spectrum."
The U.S. FDA wants more data on PTC-518 before PTC Therapeutics Inc.'s phase II study of Huntington’s disease can continue enrollment. While stopped in the U.S., the study of the oral, small-molecule splicing modifier still is enrolling participants at sites in several European countries and in Australia.
The use of cannabis and childhood trauma have been proposed as environmental factors impacting the risk of psychosis. Recent findings have suggested a link between genetic variants in the cannabinoid receptor 1 gene (CNR1) and cannabis use with the risk of psychosis development.
Medshine Discovery Inc. has presented new pyrimidine derivatives acting as leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of neurodegeneration.
RSS
